Видео ютуба по тегу Biocon Group Business Outlook

Biocon Turns 40, CMD Kiran Mazumdar Shaw Talks On Biocon FY19 Outlook
Biocon Turns 40, CMD Kiran Mazumdar Shaw Talks On Biocon FY19 Outlook
Biocon Biosimilars Consolidation Rationale! Eye On Capex Cycle, R&D Costs & Global Play | Business
Biocon Biosimilars Consolidation Rationale! Eye On Capex Cycle, R&D Costs & Global Play | Business
Biocon's Kiran Mazumdar Shaw On Strong Q4, Biosimilar Business & FY24 Outlook | Halftime Report
Biocon's Kiran Mazumdar Shaw On Strong Q4, Biosimilar Business & FY24 Outlook | Halftime Report
Our acquisition of Viatris business has been 'spooking the Indian investor,' biotechnology firm says
Our acquisition of Viatris business has been 'spooking the Indian investor,' biotechnology firm says
Biocon: Business Outlook, Kiran Mazumdar Shaw in conversation with ET Now, Mar 18, 2014
Biocon: Business Outlook, Kiran Mazumdar Shaw in conversation with ET Now, Mar 18, 2014
Biocon Set For New Biosimilar Launch
Biocon Set For New Biosimilar Launch
Biocon Appoints Peter Bains As Group CEO To Drive 'Synergistic' Growth: What's The Road Ahead?
Biocon Appoints Peter Bains As Group CEO To Drive 'Synergistic' Growth: What's The Road Ahead?
Biocon Biologics Q4 Result 2025: PAT Jumps 2.5x, Demand & Price Environment Outlook | Business News
Biocon Biologics Q4 Result 2025: PAT Jumps 2.5x, Demand & Price Environment Outlook | Business News
Biocon Biologics Q3: Biosimilars Revenue Up 54%, EBITDA Up 53% YoY
Biocon Biologics Q3: Biosimilars Revenue Up 54%, EBITDA Up 53% YoY
Why Are Analysts Betting On Biocon Shares? Detailed Analysis On Know Your Company | NDTV Profit
Why Are Analysts Betting On Biocon Shares? Detailed Analysis On Know Your Company | NDTV Profit
Biocon Biologics Restructures Deal With SII | Nithya Balasubramanian Speaks On This & More
Biocon Biologics Restructures Deal With SII | Nithya Balasubramanian Speaks On This & More
Exclusive | Biocon Biologics Q4: Serum Will Double Investment To $300 Mn
Exclusive | Biocon Biologics Q4: Serum Will Double Investment To $300 Mn
How Biocon Is Driving Market Expansion
How Biocon Is Driving Market Expansion
CEO of India's Biocon discusses first-quarter results
CEO of India's Biocon discusses first-quarter results
Biocon's Kiran Mazumdar Shaw Discusses Biosimilar Opportunities, 2023 Outlook | CNBC-TV18
Biocon's Kiran Mazumdar Shaw Discusses Biosimilar Opportunities, 2023 Outlook | CNBC-TV18
Press Meet: Biocon Biologics To Acquire Viatris' Biosimilars Business For Global Leadership
Press Meet: Biocon Biologics To Acquire Viatris' Biosimilars Business For Global Leadership
Biologics Business Lifts Biocon’s Upbeat Quarter: #Q3WithBQ
Biologics Business Lifts Biocon’s Upbeat Quarter: #Q3WithBQ
Biocon Founder on Equality in India's Biopharmaceutical Sector
Biocon Founder on Equality in India's Biopharmaceutical Sector
Biocon Ltd concall for Q2FY26 #Bioconconcall #Biocon
Biocon Ltd concall for Q2FY26 #Bioconconcall #Biocon
Узнайте о глобальной возможности привлечения 7 миллиардов долларов для двух биоаналогов деносумаб...
Узнайте о глобальной возможности привлечения 7 миллиардов долларов для двух биоаналогов деносумаб...
Biocon Biologics is well-placed to take advantage of opportunities in the biosimilars space: CEO
Biocon Biologics is well-placed to take advantage of opportunities in the biosimilars space: CEO